Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

Introduction Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor s...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Patrick Michl, Peter Schirmacher, Andreas Teufel, Christoph Springfeld, Dirk Jäger, Anastasia Tsakmaklis, Anja Sander, Arne Kandulski, Conrad Rauber, Maria Paula Roberti, Maria JGT Vehreschild, Thomas Ettrich, Leonie Jochheim, Pavlos Missios, Raphael Mohr, Alexander Reichart, Dirk T Waldschmidt, Lukas D Sauer, Michael T Dill
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	BMJ Publishing Group 2025-09-01
Reeks:	BMJ Open
Online toegang:	https://bmjopen.bmj.com/content/15/9/e097802.full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!